Promising Data for Investigational Innovative Bispecific Ivo

Data Supporting Summit’s Planned Phase III Trial for First-line Metastatic Squamous NSCLC Patients on Display


Phase II ORR of 67% with a mDOR of 15 months in 1L SQ-NSCLC Patients

... | June 4, 2023

Related Keywords

Li Zhang , Zhejiang , China , Yu Zhang , Canada , California , United States , United Kingdom , Li Zhuang , Henan , Weifeng , Shaanxi , Ming Zhou , Anhui , Wu Zhuang , Chicago , Illinois , Australia , Japan , Menlo Park , Yingying , Liaoning , American , Yuanyuan Zhao , Michelle Xia , Likun Chen , Yanqiu Zhao , Qitao Yu , Jianhua Chen , Bryan Huang , Yunpeng Yang , Ningning Zhou , Weidong Zhang , Wenfeng Fang , American Cancer Society , Summit Therapeutics Inc , American Society Of Clinical Oncology , Drug Administration , Team Summit , Exchange Commission , Summit Therapeutic Mission Statement , Sun Yat Sen University Cancer Center , Akeso Inc , Twitter , Nasdaq , World Health Organization , Summit Therapeutics , Clinical Oncology , Annual Meeting , Board Number , Lung Cancer , Non Small Cell Metastatic Poster , Sunday June , Nasdaq Global Market , Private Securities Litigation Reform Act , Yixin Wan , Weifeng Song , Cancer Society , Lung Cancer Statistics , Show Common , Health Organization , Cancer Epidemiology , Summit Therapeutics Inc Stock Exchange , News , Information , Press Release , Data , Supporting , Planned , Hase , Wii , Trial , Or , Metastatic , Squamous , Nsclc , Patients , N , Hi , Rr , F , Ith , Odor , 5 , Months , L Smmt Us86627t1088 ,